MHRA Study Shows Mouse Model Success for Needle-Free Strep A Vaccine Technology

What was announced

The Medicines and Healthcare products Regulatory Agency (MHRA) announced findings from a pre-clinical study on a potential vaccine for group A streptococcus (Strep A). Scientists from the MHRA worked alongside the GSK Vaccines Institute for Global Health on the project. They published their results in the journal Human Vaccines & Immunotherapeutics in October 2026.

Researchers examined a needle-free delivery method using nasal drops or sprays, as well as application under the tongue. They used Generalised Modules for Membrane Antigens (GMMA), which are tiny bubbles naturally released by bacteria. In the study, GMMA served two roles: carrying the Strep A carbohydrate and acting as an adjuvant. An adjuvant is an ingredient that helps trigger a stronger immune response.

Testing took place in a mouse model. The agency reported that the method produced immune responses at mucosal surfaces in the nose and throat, as well as systemic immune responses across the wider body.

What it means

Strep A causes over 600 million annual infections globally and leads to more than 500,000 deaths each year through severe complications. Currently, no licensed vaccine exists to protect people against the bacterium.

Most conventional vaccines focus on building antibodies in the bloodstream via intramuscular injections. This experimental approach instead targets the mucosal surfaces where Strep A first enters the body. Dr Fatme Mawas, Head of Conjugate Vaccines at the MHRA, stated that generating immune protection at infection entry points could support defense against invasive forms of the disease.

Delivering vaccines through the nose or under the tongue removes the need for needles. The MHRA noted that needle-free options could simplify administration and improve access to immunisations, particularly in low- and middle-income countries where Strep A disease burdens remain highest. The agency added that preventing bacterial infections through vaccination may reduce reliance on antibiotics and assist global efforts against antimicrobial resistance.

What the announcement does not tell us

The announcement does not state when human clinical trials might begin. Because the study involved only mice, further research is required before any human testing can take place.

The MHRA did not provide details on manufacturing costs, production timelines, or specific storage requirements for GMMA-based vaccines. Additionally, the announcement does not specify which Strep A strains were targeted in the trial or how long the observed immune response lasted in the test animals.